Recombinant P. falciparum merozoite protein-142 vaccine
AssigneesThe United States of America as represented by the Secretary of the Army, Glaxosmithkline Biologicals SA
InventorsEvelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
Life of this patent
Estimating the term…
Abstract
In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.
Claims17
A recombinant merozoite surface protein-1 (MSP-142) from P. falciparum FVO comprising the sequence set forth as SEQ ID NO:2 that is recombinantly expressed in E. coli as a soluble protein that retains its native folding.
Dependencies are inferred from the claim text.